Shares of Cancer Genetics Inc (NASDAQ:CGIX) have been given a consensus rating of “Hold” by the six analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $6.00.
Several analysts recently issued reports on CGIX shares. ValuEngine cut Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Cancer Genetics in a research report on Thursday, September 21st. Zacks Investment Research cut Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Finally, Maxim Group started coverage on Cancer Genetics in a research report on Thursday. They set a “buy” rating and a $6.00 target price for the company.
Several large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its stake in Cancer Genetics by 61.0% during the second quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after buying an additional 12,168 shares during the last quarter. KCG Holdings Inc. bought a new position in Cancer Genetics during the first quarter valued at approximately $102,000. Granahan Investment Management Inc. MA boosted its stake in Cancer Genetics by 26.3% during the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after buying an additional 49,371 shares during the last quarter. Thompson Davis & CO. Inc. boosted its stake in Cancer Genetics by 5,465.0% during the second quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after buying an additional 109,300 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in Cancer Genetics by 44.8% during the first quarter. Renaissance Technologies LLC now owns 449,600 shares of the medical research company’s stock valued at $1,843,000 after buying an additional 139,200 shares during the last quarter. Hedge funds and other institutional investors own 12.71% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Cancer Genetics Inc (CGIX) Given Consensus Rating of “Hold” by Analysts” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.chaffeybreeze.com/2017/12/07/cancer-genetics-inc-cgix-given-consensus-rating-of-hold-by-analysts.html.
Cancer Genetics Company Profile
Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.
Receive News & Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.